Dr. Yaguang Xi's lab at the University of Georgia focuses on developing new therapies for difficult-to-treat breast cancer, particularly triple-negative breast cancer (TNBC). They are investigating a new compound called LG007, which has shown promise in shrinking tumors and inhibiting cancer spread in preclinical models. The lab combines molecular biology techniques with advanced animal models to understand the drug's actions and prepare for possible clinical trials.

Dr. David Crich's lab focuses on developing next-generation aminoglycoside antibiotics that are effective against multidrug-resistant bacteria while minimizing side effects like hearing loss and kidney damage. By synthesizing and optimizing new compounds, the lab aims to create more effective treatments with improved safety profiles. Research includes a combination of laboratory assays and animal models to test efficacy and toxicity.